Well, they need to generate revenue and build an actual business. Right now both companies are a bunch of empty promises used to raise toxic debt and dump it.
ENDV had over a billion shares OS before they reversed it 1-1000. Biel has 22 billion OS but its market cap was also like 25x that of ENDV, think about that. BIEL has been diluting since 2004 ENDV since 2014 so 10 years head start.
Reverse stock splits destroy shareholders especially when paired with toxic financings. This has all the hallmarks of a pump and dump scheme.
Ask yourself this question: If BIEL's device costs like $27 bucks, has clinical trials showing it reduces post-surgical pain and edema comparable to SofPulse, and yet doesn't sell even $250k per year in sales, what real probability do you think ENDV will have to generate tens of millions in revenue if their device is 10x more expensive and requires a prescription?
News 
Market Data 
Discover 
